exenatide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 1123 141758-74-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • exenatide
  • byetta
  • exenatide synthetic
  • bydureon
  • exendin-4
  • AC002993
  • AC2993A
A synthetic form of exendin-4, a 39-amino acid peptide isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exenatide increases CYCLIC AMP levels in pancreatic acinar cells and acts as a GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist and incretin mimetic, enhancing insulin secretion in response to increased glucose levels; it also suppresses inappropriate glucagon secretion and slows gastric emptying. It is used an anti-diabetic and anti-obesity agent.
  • Molecular weight: 4186.63
  • Formula: C184H282N50O60S
  • CLOGP:
  • LIPINSKI: None
  • HAC: 110
  • HDO: 58
  • TPSA: 1749.75
  • ALOGS:
  • ROTB: 134

Drug dosage:

DoseUnitRoute
0.29 mg P
15 mcg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 25 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
April 28, 2005 FDA ASTRAZENECA AB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 1953.03 17.12 730 22172 41884 50540338
Blood glucose increased 1865.55 17.12 816 22086 70508 50511714
Weight decreased 1137.46 17.12 876 22026 220369 50361853
Injection site nodule 922.81 17.12 229 22673 3119 50579103
Nausea 547.32 17.12 1063 21839 704335 49877887
Blood glucose decreased 541.63 17.12 229 22673 17982 50564240
Pancreatitis acute 369.60 17.12 191 22711 23621 50558601
Injection site pruritus 319.22 17.12 209 22693 40202 50542020
Injection site mass 312.15 17.12 149 22753 15531 50566691
Glycosylated haemoglobin increased 300.71 17.12 129 22773 10477 50571745
Injection site haemorrhage 299.30 17.12 160 22742 21186 50561036
Injection site extravasation 262.40 17.12 106 22796 7395 50574827
Vomiting 203.48 17.12 559 22343 460199 50122023
Injection site urticaria 201.06 17.12 102 22800 12115 50570107
Injection site pain 197.44 17.12 247 22655 110777 50471445
Hypoglycaemia 179.94 17.12 167 22735 53414 50528808
Decreased appetite 179.82 17.12 324 22578 200599 50381623
Injection site rash 163.73 17.12 98 22804 16079 50566143
Blood glucose abnormal 159.48 17.12 72 22830 6600 50575622
Injection site erythema 154.83 17.12 180 22722 74756 50507466
Pancreatic carcinoma 154.72 17.12 69 22833 6145 50576077
Injection site bruising 141.94 17.12 124 22778 36644 50545578
Incorrect dose administered by device 128.06 17.12 51 22851 3424 50578798
Device leakage 126.58 17.12 59 22843 5819 50576403
Lipase increased 122.40 17.12 65 22837 8476 50573746
Blood glucose fluctuation 116.06 17.12 50 22852 4096 50578126
Wrong technique in device usage process 111.19 17.12 42 22860 2444 50579778
Injection site irritation 110.53 17.12 49 22853 4301 50577921
Early satiety 108.42 17.12 31 22871 741 50581481
Incorrect dose administered 107.89 17.12 121 22781 48293 50533929
Diabetic ketoacidosis 100.22 17.12 75 22827 17797 50564425
Pancreatitis chronic 97.46 17.12 37 22865 2183 50580039
Product quality issue 93.66 17.12 91 22811 30767 50551455
Cholelithiasis 93.45 17.12 100 22802 37873 50544349
Diabetes mellitus inadequate control 91.70 17.12 63 22839 13082 50569140
Device malfunction 83.76 17.12 63 22839 15058 50567164
Intentional device misuse 80.06 17.12 24 22878 680 50581542
Pancreatic carcinoma metastatic 75.35 17.12 30 22872 2012 50580210
Urticaria 74.19 17.12 174 22728 129387 50452835
Underdose 73.46 17.12 66 22836 20212 50562010
Injury associated with device 72.46 17.12 33 22869 3084 50579138
Eructation 69.09 17.12 42 22860 7079 50575143
Impaired gastric emptying 68.52 17.12 45 22857 8673 50573549
Hyperglycaemia 66.17 17.12 82 22820 36323 50545899
Injection site swelling 64.81 17.12 87 22815 41686 50540536
Pain 64.33 17.12 102 22800 578801 50003421
Drug ineffective 61.52 17.12 180 22722 819153 49763069
Toxicity to various agents 59.35 17.12 12 22890 212487 50369735
Device issue 58.91 17.12 58 22844 19914 50562308
Amylase increased 57.81 17.12 34 22868 5396 50576826
Adenocarcinoma pancreas 55.81 17.12 20 22882 1002 50581220
Joint swelling 55.22 17.12 21 22881 245265 50336957
Nodule 55.09 17.12 52 22850 16951 50565271
Death 51.56 17.12 43 22859 325336 50256886
Rheumatoid arthritis 49.64 17.12 15 22887 202535 50379687
Systemic lupus erythematosus 48.65 17.12 4 22898 140618 50441604
Treatment failure 47.38 17.12 4 22898 137633 50444589
Drug intolerance 47.28 17.12 20 22882 219084 50363138
Arthralgia 47.05 17.12 79 22823 438623 50143599
Neutropenia 46.57 17.12 6 22896 147959 50434263
Pneumonia 46.52 17.12 62 22840 378339 50203883
Abdominal pain 45.95 17.12 220 22682 236008 50346214
Blood triglycerides increased 45.34 17.12 39 22863 11273 50570949
Pyrexia 45.03 17.12 64 22838 380139 50202083
Pancreatitis necrotising 43.48 17.12 18 22884 1335 50580887
Acute kidney injury 42.63 17.12 210 22692 227848 50354374
Fatigue 42.44 17.12 171 22731 707430 49874792
Lactic acidosis 42.16 17.12 63 22839 33292 50548930
Circumstance or information capable of leading to medication error 42.14 17.12 23 22879 3165 50579057
Hunger 40.98 17.12 25 22877 4238 50577984
Injection site abscess 40.76 17.12 16 22886 1033 50581189
Device delivery system issue 40.39 17.12 13 22889 468 50581754
Increased appetite 40.12 17.12 32 22870 8329 50573893
Injection site haematoma 39.81 17.12 28 22874 6032 50576190
Medication error 39.77 17.12 64 22838 36040 50546182
Dehydration 39.62 17.12 155 22747 152294 50429928
Injection site inflammation 39.28 17.12 22 22880 3183 50579039
Musculoskeletal stiffness 38.58 17.12 6 22896 128475 50453747
Wound 36.61 17.12 3 22899 105791 50476431
White blood cell count decreased 36.09 17.12 5 22897 116717 50465505
Arthropathy 34.71 17.12 14 22888 157892 50424330
Infection 33.90 17.12 18 22884 172936 50409286
Hepatic steatosis 33.63 17.12 48 22854 24336 50557886
Feeling jittery 32.15 17.12 32 22870 11128 50571094
Thrombocytopenia 32.10 17.12 9 22893 127664 50454558
Peripheral swelling 31.62 17.12 28 22874 205908 50376314
Needle issue 31.03 17.12 26 22876 7249 50574973
Pancreatitis relapsing 30.72 17.12 12 22890 765 50581457
Febrile neutropenia 30.63 17.12 4 22898 97663 50484559
Abdominal distension 29.45 17.12 86 22816 72817 50509405
Thyroid cancer 29.11 17.12 20 22882 4149 50578073
Device defective 27.88 17.12 13 22889 1282 50580940
General physical health deterioration 27.64 17.12 15 22887 142419 50439803
Nasopharyngitis 27.55 17.12 28 22874 192899 50389323
Sinusitis 26.41 17.12 23 22879 170535 50411687
Alopecia 26.32 17.12 44 22858 245003 50337219
Injection site cellulitis 25.93 17.12 12 22890 1163 50581059
Injection site induration 25.91 17.12 25 22877 8372 50573850
Stomatitis 25.74 17.12 7 22895 101337 50480885
Product dose omission issue 25.38 17.12 156 22746 183682 50398540
Cough 25.29 17.12 44 22858 241220 50341002
Product quality control issue 25.27 17.12 5 22897 21 50582201
Pancreatitis haemorrhagic 24.67 17.12 8 22894 295 50581927
Body mass index abnormal 24.63 17.12 6 22896 75 50582147
Intentional product use issue 24.48 17.12 3 22899 76915 50505307
Disease progression 23.65 17.12 7 22895 95859 50486363
Congenital intestinal malformation 23.14 17.12 4 22898 6 50582216
Dyspnoea 22.72 17.12 150 22752 547458 50034764
Vomiting projectile 22.43 17.12 11 22891 1213 50581009
Therapeutic product effect incomplete 22.00 17.12 7 22895 91508 50490714
Medullary thyroid cancer 21.99 17.12 6 22896 120 50582102
Pancreatic duct stenosis 21.92 17.12 5 22897 46 50582176
Drug interaction 21.28 17.12 36 22866 199585 50382637
Hypoglycaemic unconsciousness 21.17 17.12 9 22893 713 50581509
Angioedema 20.87 17.12 50 22852 37626 50544596
Bile duct stent insertion 20.86 17.12 5 22897 58 50582164
Swelling 20.71 17.12 37 22865 200835 50381387
Platelet count decreased 20.44 17.12 10 22892 100716 50481506
Confusional state 20.31 17.12 33 22869 185895 50396327
Discomfort 20.18 17.12 12 22890 108368 50473854
Injection site indentation 20.18 17.12 6 22896 165 50582057
Injection site warmth 20.16 17.12 28 22874 13838 50568384
Cholecystitis 20.15 17.12 28 22874 13843 50568379
Product use in unapproved indication 19.97 17.12 14 22888 115805 50466417
Weight increased 19.45 17.12 157 22745 201734 50380488
Intestinal malrotation 19.24 17.12 7 22895 366 50581856
Injection site infection 19.18 17.12 11 22891 1665 50580557
Product prescribing error 18.90 17.12 34 22868 20927 50561295
Hyponatraemia 18.83 17.12 10 22892 96129 50486093
Renal failure 18.34 17.12 96 22806 106537 50475685
Hypotension 18.05 17.12 51 22851 235418 50346804
Pancreatic neoplasm 18.04 17.12 8 22894 702 50581520
Gait disturbance 17.95 17.12 25 22877 149980 50432242
Product use issue 17.80 17.12 25 22877 149450 50432772
Product dispensing error 17.73 17.12 21 22881 8870 50573352
Nail growth abnormal 17.51 17.12 7 22895 474 50581748
Loss of personal independence in daily activities 17.48 17.12 5 22897 70045 50512177
Cardiac arrest 17.44 17.12 8 22894 83643 50498579
Metastases to liver 17.35 17.12 32 22870 20072 50562150

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 1759.92 17.55 674 15700 33840 29524313
Blood glucose increased 1081.35 17.55 563 15811 58421 29499732
Injection site nodule 924.99 17.55 204 16170 1266 29556887
Weight decreased 764.52 17.55 644 15730 150261 29407892
Pancreatitis acute 474.46 17.55 243 16131 24142 29534011
Pancreatic carcinoma 310.96 17.55 125 16249 7025 29551128
Nausea 298.53 17.55 554 15820 288701 29269452
Injection site mass 292.45 17.55 111 16263 5344 29552809
Injection site haemorrhage 262.34 17.55 116 16258 8270 29549883
Blood glucose decreased 254.11 17.55 127 16247 11942 29546211
Device leakage 232.06 17.55 89 16285 4406 29553747
Injection site extravasation 227.98 17.55 75 16299 2358 29555795
Injection site pain 226.24 17.55 168 16206 32278 29525875
Glycosylated haemoglobin increased 221.74 17.55 107 16267 9319 29548834
Blood glucose abnormal 154.71 17.55 69 16305 5014 29553139
Incorrect dose administered by device 146.42 17.55 48 16326 1491 29556662
Injection site pruritus 145.45 17.55 69 16305 5780 29552373
Cholelithiasis 137.52 17.55 100 16274 18572 29539581
Intentional device misuse 125.60 17.55 27 16347 145 29558008
Pancreatic carcinoma metastatic 123.20 17.55 49 16325 2672 29555481
Lipase increased 116.97 17.55 67 16307 8270 29549883
Wrong technique in device usage process 99.84 17.55 33 16341 1052 29557101
Hypoglycaemia 94.71 17.55 125 16249 48221 29509932
Product quality issue 94.64 17.55 75 16299 15820 29542333
Injection site erythema 89.91 17.55 69 16305 13887 29544266
Underdose 86.08 17.55 63 16311 11806 29546347
Device malfunction 84.96 17.55 55 16319 8452 29549701
Adenocarcinoma pancreas 84.25 17.55 30 16344 1201 29556952
Vomiting 82.31 17.55 281 16093 211979 29346174
Diabetes mellitus inadequate control 80.38 17.55 61 16313 12073 29546080
Injection site urticaria 73.15 17.55 29 16345 1567 29556586
Decreased appetite 72.43 17.55 210 16164 145132 29413021
Toxicity to various agents 71.05 17.55 7 16367 173654 29384499
Blood glucose fluctuation 67.35 17.55 35 16339 3562 29554591
Device issue 67.30 17.55 46 16328 7734 29550419
Incorrect dose administered 67.22 17.55 87 16287 32897 29525256
Injection site bruising 63.64 17.55 44 16330 7536 29550617
Pancreatitis chronic 63.20 17.55 28 16346 2000 29556153
Death 58.66 17.55 62 16312 342022 29216131
Pancreatitis necrotising 56.24 17.55 27 16347 2320 29555833
Needle issue 53.57 17.55 33 16341 4650 29553503
Pyrexia 51.69 17.55 50 16324 287572 29270581
Pancreaticoduodenectomy 51.33 17.55 11 16363 58 29558095
Injection site swelling 50.88 17.55 42 16332 9375 29548778
Neutropenia 49.65 17.55 7 16367 131704 29426449
Cholecystectomy 49.54 17.55 25 16349 2392 29555761
Diabetic ketoacidosis 48.75 17.55 52 16322 16021 29542132
Injection site rash 48.27 17.55 28 16346 3536 29554617
Metastases to liver 48.24 17.55 45 16329 11811 29546342
Injection site irritation 47.72 17.55 19 16355 1038 29557115
Pneumonia 47.44 17.55 65 16309 320107 29238046
Thrombocytopenia 44.67 17.55 10 16364 134813 29423340
Injection site reaction 44.62 17.55 42 16332 11146 29547007
Injection site abscess 43.72 17.55 16 16358 693 29557460
Nodule 43.68 17.55 30 16344 5082 29553071
Device delivery system issue 42.48 17.55 13 16361 321 29557832
Amylase increased 40.49 17.55 29 16345 5251 29552902
Drug delivery system issue 39.00 17.55 6 16368 0 29558153
Hepatic steatosis 37.84 17.55 44 16330 14902 29543251
Anaemia 37.13 17.55 34 16340 200917 29357236
Blood triglycerides increased 34.54 17.55 39 16335 12795 29545358
Disease progression 34.26 17.55 3 16371 81913 29476240
Product use in unapproved indication 34.21 17.55 4 16370 86871 29471282
Platelet count decreased 34.19 17.55 8 16366 104664 29453489
Impaired gastric emptying 33.51 17.55 21 16353 3049 29555104
Drug abuse 33.21 17.55 3 16371 79880 29478273
Drug dose omission by device 32.64 17.55 15 16359 1167 29556986
Pancytopenia 32.33 17.55 4 16370 83164 29474989
Circumstance or information capable of leading to medication error 31.93 17.55 16 16358 1508 29556645
Renal failure 31.83 17.55 140 16234 118459 29439694
Malignant neoplasm progression 30.10 17.55 3 16371 73856 29484297
White blood cell count decreased 30.09 17.55 5 16369 83357 29474796
Pancreatic neuroendocrine tumour 29.73 17.55 9 16365 214 29557939
Hyperglycaemia 29.24 17.55 61 16313 34226 29523927
Abdominal pain upper 29.19 17.55 87 16287 60906 29497247
Injection site induration 29.07 17.55 18 16356 2558 29555595
Bile duct stent insertion 28.66 17.55 7 16367 71 29558082
Abdominal pain 28.51 17.55 149 16225 135208 29422945
General physical health deterioration 27.93 17.55 11 16363 102846 29455307
Pancreatic neoplasm 27.46 17.55 12 16362 829 29557324
Fatigue 26.94 17.55 88 16286 316733 29241420
Pancreatitis haemorrhagic 26.42 17.55 9 16365 315 29557838
Pancreatic stent placement 26.39 17.55 5 16369 12 29558141
Drug interaction 26.31 17.55 43 16331 197342 29360811
Injection site cellulitis 26.07 17.55 10 16364 494 29557659
Biliary dyskinesia 25.84 17.55 6 16368 48 29558105
Therapeutic product effect decreased 25.82 17.55 53 16321 29398 29528755
Early satiety 25.26 17.55 10 16364 538 29557615
Eructation 24.04 17.55 19 16355 3987 29554166
Hepatic cancer 23.41 17.55 23 16351 6433 29551720
Distributive shock 22.60 17.55 11 16363 974 29557179
Pancreatic cyst 22.39 17.55 10 16364 728 29557425
Haemoglobin decreased 21.62 17.55 17 16357 108358 29449795
Pancreatic pseudocyst 21.62 17.55 10 16364 790 29557363
Feeling jittery 21.30 17.55 17 16357 3616 29554537
Pancreatic enzymes increased 21.26 17.55 9 16365 575 29557578
Injection site haematoma 20.70 17.55 12 16362 1513 29556640
Leukopenia 20.62 17.55 3 16371 55200 29502953
Insulin-requiring type 2 diabetes mellitus 20.57 17.55 6 16368 125 29558028
Interstitial lung disease 19.67 17.55 4 16370 57714 29500439
Injection site discomfort 19.58 17.55 11 16363 1306 29556847
Pancreatic duct dilatation 19.56 17.55 5 16369 62 29558091
Seizure 19.35 17.55 14 16360 93109 29465044
Hunger 19.34 17.55 11 16363 1338 29556815
Dehydration 19.31 17.55 119 16255 114629 29443524
Hypoglycaemic unconsciousness 18.96 17.55 9 16365 754 29557399
Weight increased 18.67 17.55 88 16286 76579 29481574
Glycosylated haemoglobin decreased 18.44 17.55 7 16367 336 29557817
Diverticulum 18.34 17.55 20 16354 6312 29551841
Cholecystitis chronic 18.17 17.55 9 16365 827 29557326
Hyperlipidaemia 17.92 17.55 28 16346 12562 29545591
Therapeutic response unexpected 17.92 17.55 23 16351 8615 29549538
Injection site injury 17.86 17.55 6 16368 201 29557952
Confusional state 17.83 17.55 27 16347 127850 29430303

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 2019.68 17.67 877 21583 97196 64379076
Pancreatitis 1552.64 17.67 631 21829 58976 64417296
Injection site nodule 1033.43 17.67 237 22223 2993 64473279
Weight decreased 1010.03 17.67 815 21645 284924 64191348
Nausea 638.36 17.67 1042 21418 784758 63691514
Blood glucose decreased 503.52 17.67 216 22244 22907 64453365
Pancreatitis acute 355.76 17.67 208 22252 42647 64433625
Glycosylated haemoglobin increased 323.64 17.67 142 22318 15877 64460395
Injection site haemorrhage 316.51 17.67 159 22301 24119 64452153
Injection site pruritus 309.73 17.67 182 22278 37644 64438628
Injection site mass 291.40 17.67 135 22325 17135 64459137
Vomiting 221.76 17.67 548 21912 550569 63925703
Injection site pain 220.76 17.67 231 22229 111177 64365095
Injection site extravasation 211.02 17.67 86 22374 8000 64468272
Decreased appetite 210.71 17.67 362 22098 280927 64195345
Hypoglycaemia 208.47 17.67 203 22257 89689 64386583
Incorrect dose administered by device 200.16 17.67 69 22391 4028 64472244
Pancreatic carcinoma 199.96 17.67 89 22371 10284 64465988
Device leakage 192.33 17.67 81 22379 8185 64468087
Injection site urticaria 187.32 17.67 87 22373 11094 64465178
Blood glucose abnormal 173.49 17.67 77 22383 8836 64467436
Injection site erythema 147.67 17.67 151 22309 70649 64405623
Product quality issue 141.68 17.67 102 22358 29697 64446575
Lipase increased 138.44 17.67 77 22383 14325 64461947
Wrong technique in device usage process 134.84 17.67 47 22413 2835 64473437
Incorrect dose administered 132.93 17.67 133 22327 60632 64415640
Blood glucose fluctuation 130.72 17.67 56 22404 5899 64470373
Injection site bruising 125.72 17.67 103 22357 36270 64440002
Injection site rash 116.43 17.67 71 22389 15671 64460601
Injection site irritation 111.08 17.67 42 22418 3198 64473074
Diabetic ketoacidosis 106.26 17.67 86 22374 29759 64446513
Device malfunction 94.59 17.67 65 22395 17568 64458704
Underdose 91.04 17.67 74 22386 25755 64450517
Diabetes mellitus inadequate control 90.11 17.67 68 22392 21253 64455019
Toxicity to various agents 82.04 17.67 14 22446 363499 64112773
Early satiety 79.00 17.67 25 22435 1114 64475158
Device delivery system issue 69.39 17.67 18 22442 388 64475884
Eructation 69.36 17.67 42 22418 9149 64467123
Urticaria 69.04 17.67 156 22304 147161 64329111
Cholelithiasis 68.73 17.67 82 22378 45424 64430848
Injection site swelling 64.91 17.67 76 22384 41277 64434995
Amylase increased 64.82 17.67 41 22419 9644 64466628
Pyrexia 63.19 17.67 61 22399 558583 63917689
Intentional device misuse 60.41 17.67 18 22442 654 64475618
Pneumonia 59.99 17.67 64 22396 559512 63916760
Acute kidney injury 57.61 17.67 308 22152 448932 64027340
Neutropenia 54.52 17.67 9 22451 239615 64236657
Device issue 50.27 17.67 50 22410 22598 64453674
Febrile neutropenia 50.26 17.67 4 22456 187653 64288619
Needle issue 49.30 17.67 34 22426 9238 64467034
Impaired gastric emptying 48.50 17.67 33 22427 8771 64467501
Hyperglycaemia 47.44 17.67 80 22380 60888 64415384
Pancreatic carcinoma metastatic 45.93 17.67 23 22437 3455 64472817
Thrombocytopenia 45.50 17.67 11 22449 223790 64252482
Feeling jittery 45.11 17.67 34 22426 10601 64465671
Abdominal distension 43.11 17.67 100 22360 95894 64380378
Lactic acidosis 41.82 17.67 76 22384 61334 64414938
Pancreatitis necrotising 41.68 17.67 21 22439 3196 64473076
Circumstance or information capable of leading to medication error 40.94 17.67 21 22439 3319 64472953
Dehydration 39.70 17.67 165 22295 216598 64259674
Drug delivery system issue 39.30 17.67 7 22453 20 64476252
Death 38.78 17.67 68 22392 482637 63993635
Injury associated with device 38.07 17.67 19 22441 2834 64473438
White blood cell count decreased 38.03 17.67 5 22455 157832 64318440
Injection site abscess 36.91 17.67 15 22445 1383 64474889
Injection site induration 36.65 17.67 28 22432 8904 64467368
Platelet count decreased 36.61 17.67 7 22453 167704 64308568
Injection site inflammation 35.89 17.67 19 22441 3202 64473070
Abdominal pain 34.54 17.67 206 22254 312169 64164103
Anaemia 33.53 17.67 50 22410 378630 64097642
Product use in unapproved indication 33.40 17.67 10 22450 176608 64299664
Disease progression 32.93 17.67 5 22455 141675 64334597
Adenocarcinoma pancreas 32.69 17.67 15 22445 1858 64474414
Product dose omission issue 32.38 17.67 144 22316 194603 64281669
Injection site cellulitis 32.38 17.67 14 22446 1507 64474765
Medication error 31.71 17.67 60 22400 49906 64426366
Blood triglycerides increased 30.14 17.67 35 22425 18831 64457441
Drug intolerance 29.93 17.67 14 22446 187978 64288294
General physical health deterioration 29.91 17.67 17 22443 204408 64271864
Treatment failure 29.89 17.67 3 22457 116813 64359459
Increased appetite 29.44 17.67 26 22434 10120 64466152
Feeling abnormal 28.72 17.67 107 22353 133495 64342777
Joint swelling 28.63 17.67 20 22440 215362 64260910
Malignant neoplasm progression 28.62 17.67 3 22457 112868 64363404
Rheumatoid arthritis 28.12 17.67 11 22449 164283 64311989
Pain 27.98 17.67 99 22361 553412 63922860
Device defective 27.94 17.67 12 22448 1271 64475001
Ketoacidosis 27.04 17.67 21 22439 6842 64469430
Therapeutic product effect decreased 27.01 17.67 95 22365 115256 64361016
Hyponatraemia 26.97 17.67 9 22451 148330 64327942
Injection site indentation 26.64 17.67 7 22453 159 64476113
Drug dose omission by device 26.60 17.67 16 22444 3441 64472831
Hunger 25.87 17.67 17 22443 4264 64472008
Cough 24.73 17.67 42 22418 302106 64174166
Injection site haematoma 24.69 17.67 16 22444 3920 64472352
Injection site infection 23.65 17.67 12 22448 1853 64474419
Injection site reaction 23.61 17.67 51 22409 46613 64429659
Nodule 23.32 17.67 30 22430 17917 64458355
Dyspepsia 23.16 17.67 71 22389 80241 64396031
Oxygen saturation decreased 22.29 17.67 5 22455 107171 64369101
Peripheral swelling 22.24 17.67 24 22436 209129 64267143
Device failure 21.52 17.67 17 22443 5675 64470597
Seizure 21.52 17.67 16 22444 166876 64309396
Musculoskeletal stiffness 21.49 17.67 8 22452 123198 64353074
Therapeutic response unexpected 21.44 17.67 28 22432 16973 64459299
Hyperhidrosis 21.22 17.67 93 22367 124827 64351445
Glycosylated haemoglobin decreased 21.17 17.67 8 22452 608 64475664
Stomatitis 21.09 17.67 6 22454 109599 64366673
Cardiac arrest 20.88 17.67 14 22446 154050 64322222
Distributive shock 20.72 17.67 11 22449 1864 64474408
Renal failure 20.15 17.67 120 22340 181568 64294704
Fatigue 19.98 17.67 166 22294 748564 63727708
Confusional state 19.84 17.67 38 22422 261106 64215166
Arthralgia 19.81 17.67 83 22377 442177 64034095
Cardio-respiratory arrest 19.66 17.67 5 22455 98388 64377884
Drug ineffective 19.51 17.67 193 22267 840054 63636218
Drug interaction 19.46 17.67 63 22397 362020 64114252
Interstitial lung disease 19.46 17.67 5 22455 97727 64378545
Hepatic steatosis 19.38 17.67 37 22423 30970 64445302
Coronary artery occlusion 19.29 17.67 24 22436 13867 64462405
Haemoglobin decreased 19 17.67 24 22436 195039 64281233
Pancreatitis chronic 18.71 17.67 13 22447 3573 64472699
Leukopenia 18.65 17.67 6 22454 101236 64375036
Lower respiratory tract infection 18.54 17.67 5 22455 94609 64381663
Hypotension 18.00 17.67 70 22390 380904 64095368
Pancreatitis haemorrhagic 17.96 17.67 7 22453 578 64475694
Infection 17.74 17.67 23 22437 184857 64291415

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BJ01 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D019440 Anti-Obesity Agents
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D054795 Incretins
FDA EPC N0000178480 GLP-1 Receptor Agonist
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:64088 incretin mimetics
CHEBI has role CHEBI:71196 GLP-1 receptor agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Type 2 Diabetes Mellitus Treatment Adjunct indication
Alcoholism contraindication 7200002
Acute vomiting contraindication 23971007
Dehydration contraindication 34095006
Hypertensive disorder contraindication 38341003 DOID:10763
Acute nephropathy contraindication 58574008
Transplant of kidney contraindication 70536003
Pancreatitis contraindication 75694006 DOID:4989
Chronic renal failure syndrome contraindication 90688005
Impaired renal function disorder contraindication 197663003
Gastroparesis contraindication 235675006
Hypoglycemic disorder contraindication 237630007
Calculus in biliary tract contraindication 266474003
Severe diarrhea contraindication 409587002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.15 acidic
pKa2 3.62 acidic
pKa3 3.86 acidic
pKa4 4.07 acidic
pKa5 4.31 acidic
pKa6 4.6 acidic
pKa7 12.09 acidic
pKa8 12.31 acidic
pKa9 12.61 acidic
pKa10 12.68 acidic
pKa11 12.87 acidic
pKa12 12.92 acidic
pKa13 12.99 acidic
pKa14 13.18 acidic
pKa15 13.2 acidic
pKa16 13.29 acidic
pKa17 13.3 acidic
pKa18 13.4 acidic
pKa19 13.5 acidic
pKa20 13.51 acidic
pKa21 13.52 acidic
pKa22 13.64 acidic
pKa23 13.68 acidic
pKa24 13.77 acidic
pKa25 13.82 acidic
pKa26 13.86 acidic
pKa27 11.25 Basic
pKa28 10.81 Basic
pKa29 10.31 Basic
pKa30 7.86 Basic
pKa31 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9238076 April 15, 2024 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7612176 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8431685 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8461105 April 13, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 7456254 June 30, 2025 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 6515117 Oct. 4, 2025 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8329648 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8906851 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 9884092 Aug. 18, 2026 REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8501698 June 20, 2027 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8361972 March 21, 2028 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS 8895033 Oct. 4, 2030 STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Feb. 15, 2022 INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Feb. 15, 2022 INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Feb. 15, 2022 INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Aug. 15, 2023 PEDIATRIC EXCLUSIVITY
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Aug. 15, 2023 PEDIATRIC EXCLUSIVITY
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Aug. 15, 2023 PEDIATRIC EXCLUSIVITY
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 22, 2024 NEW PATIENT POPULATION
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 22, 2024 NEW PATIENT POPULATION
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS July 22, 2024 NEW PATIENT POPULATION
300MCG/1.2ML (250MCG/ML) BYETTA ASTRAZENECA AB N021773 April 28, 2005 RX INJECTABLE SUBCUTANEOUS Nov. 4, 2024 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
600MCG/2.4ML (250MCG/ML) BYETTA ASTRAZENECA AB N021773 April 28, 2005 RX INJECTABLE SUBCUTANEOUS Nov. 4, 2024 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
2MG BYDUREON PEN ASTRAZENECA AB N022200 Feb. 28, 2014 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Jan. 22, 2025 PEDIATRIC EXCLUSIVITY
2MG/VIAL BYDUREON ASTRAZENECA AB N022200 Jan. 27, 2012 DISCN FOR SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Jan. 22, 2025 PEDIATRIC EXCLUSIVITY
2MG/0.85ML (2MG/0.85ML) BYDUREON BCISE ASTRAZENECA AB N209210 Oct. 20, 2017 RX SUSPENSION, EXTENDED RELEASE SUBCUTANEOUS Jan. 22, 2025 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST IC50 9.18 CHEMBL CHEMBL
Glucagon-like peptide 1 receptor GPCR IC50 9.85 CHEMBL

External reference:

IDSource
4024921 VUID
N0000171592 NUI
D04121 KEGG_DRUG
4024921 VANDF
C0167117 UMLSCUI
CHEBI:64073 CHEBI
CHEMBL414357 ChEMBL_ID
D000077270 MESH_DESCRIPTOR_UI
DB01276 DRUGBANK_ID
1135 IUPHAR_LIGAND_ID
8219 INN_ID
9P1872D4OL UNII
45588096 PUBCHEM_CID
1242964 RXNORM
184698 MMSL
19812 MMSL
d05529 MMSL
010772 NDDF
416859008 SNOMEDCT_US
417734003 SNOMEDCT_US
CHEMBL1210015 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6512 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6512 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6524 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
Byetta HUMAN PRESCRIPTION DRUG LABEL 1 0310-6524 INJECTION 250 ug SUBCUTANEOUS NDA 29 sections
BYDUREON HUMAN PRESCRIPTION DRUG LABEL 1 0310-6530 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON HUMAN PRESCRIPTION DRUG LABEL 1 0310-6530 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON BCise HUMAN PRESCRIPTION DRUG LABEL 1 0310-6540 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYDUREON BCise HUMAN PRESCRIPTION DRUG LABEL 1 0310-6540 INJECTION, SUSPENSION, EXTENDED RELEASE 2 mg SUBCUTANEOUS NDA 29 sections
BYETTA HUMAN PRESCRIPTION DRUG LABEL 1 54868-5384 INJECTION 250 ug SUBCUTANEOUS NDA 30 sections